Substandard, falsified and unregistered medicines in Latin America, 2017-2018
Bibliographic Data
| ID | 14967799 |
|---|---|
| Authors | Robin Rojas-Cortés (0000-0002-4046-9298, Regional Network for the Prevention, Detection and Response to Substandard and Falsified Medical Products in the Americas, Washington, DC, United States of America, corresponding author) |
| Year | 2020 |
| Volume | 44 |
| Pages | 1 |
| Publication date | 2020-10-06 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Revista Panamericana de Salud Pública (JOURNAL) |
| Journal identifiers | ISSN: 1020-4989 • E-ISSN: 1680-5348 |
| Publisher | Pan American Health Organization (PUBLISHER • US) |
| DOI | 10.26633/rpsp.2020.125 |
| PMID | 33033498 |
| OpenAlex | W3089456063 |
| Language | EN |
| Citations received | 7 |
| References cited | 13 |
Objective. To assess all the incidents of substandard, falsified and unregistered medicines in 2017 and 2018 in Latin America, determining the types of products affected, stages of the supply chain in which incidents were detected, quality deviations identified in tested samples, and regulatory measures taken by authorities. Methods. A comprehensive search of the websites of the Latin American national regulatory authorities was conducted, identifying all eligible incidents during 2017-2018. Standardized values were collected from each incident for pre-determined variables: country, year, type of incident, therapeutic group, supply chain, regulatory measures and laboratory data. Results. A total of 596 incidents in 13 countries were included (236 substandard, 239 falsified, 116 unregistered and 5 stolen). The therapeutic categories with the highest incidents were: anti-infectives, medicines for pain/palliative care, hormones/contraceptives, medicines for the respiratory tract, and medicines for mental/ behavioural disorders. The most common places where incidents were detected were commercial establishment, pharmacies, health services and manufacturers. The most recurrent quality deviations were failure in parameters (appearance or physicochemical), incorrect labelling, different quantity of active pharmaceutical ingredient, presence of unknown particles, and microbiological contamination. The most frequent regulatory measures identified were alerts, withdrawals, seizures, and prohibition of marketing/distribution/use. Conclusions. In Latin America, substandard, falsified and unregistered medicines persist as a highly prevalent problem. An advanced degree of regulatory development in countries is associated with higher incident detection/reporting rates and a more comprehensive set of measures. The pharmaceutical supply chain is more vulnerable in its final node. Quality deviations identified in tested samples pose serious risks to public health
Business · Environmental health · Family medicine · Latin Americans · Medical emergency · Quality (philosophy · Supply chain · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical Quality and Counterfeiting · Marketing · Pharmacy
The hidden peril
Uncertainties about the quality of medical products globally
The quality of veterinary medicines and their implications for One Health
Análise de situações de trabalho na fiscalização sanitária de medicamentos da agência reguladora federal
Analysis of work scenarios in the sanitary enforcement of medicines from the federal regulatory agency
Vigilância e controle de medicamentos abaixo do padrão, falsificados e não registrados
Productos médicos subestándares y falsificados
| Unique citing works | 7 |
|---|---|
| Citations per year | 1,75 |
| Citation span | 2022 - 2026 (5) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 7 |